Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 206,896
  • Shares Outstanding, K 29,347
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,940 K
  • 60-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 14.50
Trade CADL with:

Options Overview Details

View History
  • Implied Volatility 138.36% ( -89.63%)
  • Historical Volatility 406.01%
  • IV Percentile 15%
  • IV Rank 35.01%
  • IV High 384.07% on 04/18/24
  • IV Low 6.03% on 04/15/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 101
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,456
  • Open Int (30-Day) 819

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.56 +411.54%
on 04/03/24
11.40 -30.00%
on 04/05/24
+6.23 (+356.00%)
since 04/01/24
3-Month
1.21 +559.50%
on 02/09/24
11.40 -30.00%
on 04/05/24
+6.66 (+504.55%)
since 02/01/24
52-Week
0.66 +1,109.09%
on 11/03/23
11.40 -30.00%
on 04/05/24
+6.62 (+486.76%)
since 05/01/23

Most Recent Stories

More News
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 1.1200 (+0.90%)
ONC.TO : 1.54 (+0.65%)
BLRX : 0.6721 (+0.40%)
IMRX : 1.5300 (+7.75%)
CADL : 7.98 (+13.19%)
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage...

CADL : 7.98 (+13.19%)
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that...

CADL : 7.98 (+13.19%)
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Cash position bolstered through debt financing to support operations into the fourth quarter of 2023...

CADL : 7.98 (+13.19%)
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

-Cash position remains strong to support operations into the fourth quarter of 2023-...

CADL : 7.98 (+13.19%)
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing...

CADL : 7.98 (+13.19%)
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain...

CADL : 7.98 (+13.19%)
Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409

Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancerTrial...

CADL : 7.98 (+13.19%)
Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

Data presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual MeetingIntra-tumoral administration of CAN-3110 elicited significant T-cell...

CADL : 7.98 (+13.19%)
Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a late clinical stage...

CADL : 7.98 (+13.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 9.37
2nd Resistance Point 8.67
1st Resistance Point 8.33
Last Price 7.98
1st Support Level 7.29
2nd Support Level 6.59
3rd Support Level 6.25

See More

52-Week High 11.40
Last Price 7.98
Fibonacci 61.8% 7.30
Fibonacci 50% 6.03
Fibonacci 38.2% 4.76
52-Week Low 0.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar